Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
|Articles|October 28, 2021
Pharmacy Clinical Pearl of the Day: Colon Cancer
Author(s)Saro Arakelians, PharmD
Chemotherapy for colorectal cancer include 5-fluorouracil (5-FU), capecitabine (Xeloda), irinotecan (Camptosar), oxaliplatin (Eloxatin), and trifluridine and tipiracil (Lonsurf).
Advertisement
Clinical Pearl of the Day: Colon Cancer
Colon cancer is a type of cancer that begins in the large intestine (colon).
Insight:
- Colon cancer typically affects older adults, though it can happen at any age.
- Symptoms may include change in bowel habits, diarrhea, constipation, rectal bleeding, persistent abdominal discomfort, weakness or fatigue, and unexplained weight loss.
- Risk factors include older age, African American race, history of colorectal cancer, inflammatory intestinal conditions, obesity, diabetes, smoking, alcohol use, and family history.
- Treatment includes polypectomy, mucosal resection, partial colectomy, lymph nodes removal, chemotherapy, radiation therapy, targeted drug therapy, immunotherapy, and palliative care.
- Some drugs used as chemotherapy for colorectal cancer include 5-fluorouracil (5-FU), capecitabine (Xeloda), irinotecan (Camptosar), oxaliplatin (Eloxatin), and trifluridine and tipiracil (Lonsurf).
Sources:
Advertisement
Related to this article
As kratom questions increase, many pharmacists and other health care professionals may remain unfamiliar it and the potential risks.
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Accelerated approval for patients who progressed on platinum and immunotherapy brings a new mechanism—and a familiar toxicity profile.
If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
Manufacturing delays, financial barriers, and complex care coordination can limit access to gene therapy, emphasizing the need for patient-centered programs and long-term follow-up.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
How Stanford Pharmacists Help Close Heart Failure Therapy Gaps
3
GLP-1s and Obesity Care: Cardiorenal Outcomes, Prescribing Considerations, and Access Barriers
4
GLP-1 Receptor Agonists and Cancer: Considerations for Specialty Pharmacists
5